Succeeding in Value Communication: Introduction
Drawn from the experiences of the BaseCase Consulting Team, this is the introduction to ‘Succeeding…
Certara2021年8月5日
DDI Regulatory Poster Child using the Simcyp Simulator: Ibrutinib (Imbruvica®)
Pharmacylics and J&J sought to bring ibrutinib, its new tyrosine kinase inhibitor therapy targeting rare…
Jim Gallagher2021年7月29日
What is BaseCase?
Developing interactive and easy-to-use stakeholder engagement content market access, medical affairs, and sales field teams…
Certara2021年7月20日
Voxelotor for Treating Sickle Cell Disease: Leveraging Dose Prediction Model for DDI Prediction Without Any Clinical Studies
In November 2019, the US FDA granted accelerated approval for Oxbryta™ (voxelotor) tablets for the…
Jim Gallagher2021年7月14日
Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers
This blog post includes key takeaways from the opening session of Certara’s first Strategic Evidence…
Certara2021年6月18日
Three Pathways have emerged in Innovative Access Agreements
The days of simply determining the market demand for a new drug as a function…
Jim Gallagher2021年6月11日
Outcomes Based Agreements
The days of simply determining the market demand for a new drug as a function…
Jim Gallagher2021年6月11日
Stakeholder perspectives: current and potential benefits
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Jim Gallagher2021年5月26日
Strengths and opportunities for HTAs and market access in Europe through case studies
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Jim Gallagher2021年5月26日
Similarities and differences between SNDS and other claim databases
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
Jim Gallagher2021年5月25日
